# Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

> **NCT01147809** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 130 (actual)

## Conditions studied

- Thrombocytopaenia

## Interventions

- **DRUG:** Eltrombopag olamine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01147809
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2015-01
- **Final completion:** 2015-03
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2016-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147809, "Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01147809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*